relapse was detected while under weekly observation in a greater proportion of patients on 5-fu ( 36 % ) compared to cmf ( 6 % ) adjuvant treatment ( p less than 0.05 ) , potentially influencing tumor burden at recurrence .
C0016360
5-fu
C0950521
cmf